Merck & Co Inc reported a higher-than-expected first-quarter profit on Tuesday and raised its earnings and sales forecasts for the year, thanks to surging sales of its blockbuster cancer immunotherapy Keytruda.
Merck’s first-quarter profit beats on Keytruda boost
